ONWARD Announces Appointment of Vivian Riefberg to Board of Directors

EINDHOVEN, The Netherlands & LAUSANNE, Switzerland & BOSTON, September 26, 2022–(COMMERCIAL WIRE)–ONWARD Medical NV (Euronext: ONWD), a medical technology company that creates innovative therapies aimed at restoring movement, independence and health to people with spinal cord injuries, today announces the appointment of Vivian Riefberg as non-executive member of its Board of Directors. Ms. Riefberg will join the Board immediately and will serve on the Compensation Committee. Her appointment to the board of directors will be subject to shareholder approval at the next general meeting.

This press release contains multimedia elements. See the full press release here: https://www.businesswire.com/news/home/20220926005512/en/

Vivian Riefberg Joins ONWARD Medical Board of Directors (Photo: Business Wire)

“Vivian Riefberg is a recognized expert in health, government and strategy. I am delighted and honored to welcome him to our Board of Directors,” said CEO Dave Marver. “Vivian brings a wealth of knowledge to the institutions we will be collaborating with to commercialize our innovative therapies, including the U.S. Veterans Health Administration. Her experience and insight will be invaluable as we strive to create an entirely new therapeutic area in neuromodulation and help people with spinal cord injuries and other motor disabilities. »

“ONWARD has the opportunity to build a very special business that is successful and impactful,” said Vivian Riefberg. “I have had the privilege of advising many leading companies during my career. ONWARD is fortunate to help people with spinal cord injuries by leveraging innovative science, technology, and intellectual property, driven by a sincere mission. »

In 2020, Ms. Riefberg retired as a senior partner at McKinsey & Company, where she held various leadership positions, including head of public sector practice for the Americas and co-head of the US healthcare practice. He has served on the McKinsey & Company Global Board of Directors and the Committee to Evaluate and Develop Global Partners. Ms. Riefberg is currently Professor of Practice at the University of Virginia Darden School of Business, where she holds the David C. Walentas Jefferson Scholars Chair. At Darden, Ms. Riefberg focuses on healthcare, consulting, and strategy in the private, public, and nonprofit sectors. She focuses on executive leadership, including leadership in times of uncertainty and crisis, healthcare solutions and innovations, and women’s leadership.

Ms. Riefberg serves on the boards of Signify Health, K Health, and Lightrock, an impact investment firm, as well as the Public Broadcasting System (PBS), Johns Hopkins Medicine, the Lorna Breen Heroes Foundation, and the National Laboratory for Educational Equity. She is also a member of the advisory board for the Smithsonian-planned Museum of American Women’s History. Previously, she served on the board of directors for the US National Institutes of Health (NIH) Clinical Center and the NIH Clinical Research Advisory Board. He has also served on the Board of Directors of the Association for a Healthier America (PHA), a nonprofit organization created to mobilize efforts to address the problem of childhood obesity, as an extension of the Let’s Move campaign of the first Lady Michelle Obama. .

Ms. Riefberg is a frequent speaker at various conferences, including the World Economic Forum in Davos. She also contributes to leading industry publications on improving health care in the US, government productivity, and women’s leadership.

He holds a BA magna cum laude in history from Harvard-Radcliffe College and an MBA with honors from Harvard Business School.

About ONWARD Medical

ONWARD is a medical technology company that creates innovative therapies to restore movement, independence and health to people with spinal cord injuries. ONWARD’s work is based on more than a decade of preclinical and basic scientific research conducted in the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered through implantable (ARC-IM) or external (ARC-EX) systems, is designed to provide targeted and programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injuries, improving their quality of life.

ONWARD has received three FDA Breakthrough Device Designations for the ARC-IM and ARC-EX systems. ARC-EX is a non-invasive external platform consisting of a portable stimulator and a wireless programmer. The first data was reported in September 2022 as part of the company’s first major study, titled Up-LIFT, evaluating the ability of ARC-EX therapy to improve upper extremity strength and function. The company is currently preparing marketing authorization applications in the United States and Europe. The ARC-IM consists of an implantable pulse generator and lead that are placed near the spinal cord. The company recently completed the first human use of its ARC-IM neurostimulator in May 2022.

ONWARD’s head office is located at the High Tech Campus in Eindhoven, the Netherlands. A major team is based in Lausanne, Switzerland, and its US presence is growing in Boston, Massachusetts, USA. To learn more about the company, visit ONWD.com. To access our 2022 financial calendar, please visit IR.ONWD.com.


Certain statements, beliefs and opinions contained in this release are forward-looking and reflect the current expectations and projections of the company or, as the case may be, the directors of the company with respect to future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions, which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could have an adverse effect on the results and the financial effects of the plans and events described in this news release. A multitude of factors, including but not limited to changes in demand, competition and technology, could cause actual events, performance or results to differ materially from developments initially planned. Forward-looking statements contained in this press release regarding past trends or activities should not be construed as a statement that such trends or activities will continue in the future. Accordingly, the company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements set forth in this press release as a result of any changes in expectations or in the events, conditions, assumptions or circumstances on which these statements are based. prospective. based. Neither the company, nor its advisers or representatives, nor any of its subsidiaries, nor any officer or employee warrants that the assumptions underlying these forward-looking statements are free from error and assumes no responsibility for the future accuracy of any forward-looking statements contained therein. in this press release or the actual occurrence of anticipated developments. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this press release.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220926005512/en/


For any questions about the company:

Press contacts:
Gunther DeBacker
+32 (0)475 903 909

For any investor inquiries:

Leave a Comment

Your email address will not be published. Required fields are marked *